Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study

Fig. 3

Forrest plot with subgroup analysis of case-fatality rates according to the clinical and laboratory characteristics. Bars to the left of the reference line indicate superiority of ruxolitinib, to the right—superiority of dexamethasone. ULN = upper limit of normal. Max = maximal value documented in-hospital before anti-cytokine therapy. The cut off levels of absolute lymphocytes and hemoglobin represent local normal reference ranges

Back to article page